Global Central Nervous System Biomarkers Market Growth (Status and Outlook) 2025-2031

According to this study, the global Central Nervous System Biomarkers market size will reach US$ 6533 million by 2031.

With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer"s disease, Parkinson"s disease, multiple sclerosis, and other neurological conditions.

United States market for Central Nervous System Biomarkers is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Central Nervous System Biomarkers is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Central Nervous System Biomarkers is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Central Nervous System Biomarkers players cover Merck, Takeda Pharmaceutical, Thermo Fisher Scientific, Avacta Group, Diagenic Asa, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Central Nervous System Biomarkers Industry Forecast” looks at past sales and reviews total world Central Nervous System Biomarkers sales in 2024, providing a comprehensive analysis by region and market sector of projected Central Nervous System Biomarkers sales for 2025 through 2031. With Central Nervous System Biomarkers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Central Nervous System Biomarkers industry.

This Insight Report provides a comprehensive analysis of the global Central Nervous System Biomarkers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Central Nervous System Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Central Nervous System Biomarkers market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Central Nervous System Biomarkers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Central Nervous System Biomarkers.

This report presents a comprehensive overview, market shares, and growth opportunities of Central Nervous System Biomarkers market by product type, application, key players and key regions and countries.

Segmentation by Type:
Safety Biomarker
Efficacy Biomarker
Validation Biomarker
Other

Segmentation by Application:
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Takeda Pharmaceutical
Thermo Fisher Scientific
Avacta Group
Diagenic Asa
Banyan Biomarkers
Eli Lilly
Pfizer
Alseres Pharmaceuticals
Acumen pharmaceuticals
EKF Diagnostics
Abiant
Myriad RBM
Aposense

Please note: The report will take approximately 2 business days to prepare and deliver. Show more